JP2006510618A - ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用 - Google Patents

ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用 Download PDF

Info

Publication number
JP2006510618A
JP2006510618A JP2004553852A JP2004553852A JP2006510618A JP 2006510618 A JP2006510618 A JP 2006510618A JP 2004553852 A JP2004553852 A JP 2004553852A JP 2004553852 A JP2004553852 A JP 2004553852A JP 2006510618 A JP2006510618 A JP 2006510618A
Authority
JP
Japan
Prior art keywords
norketamine
pain
compound
phenyl
ketamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004553852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510618A5 (enExample
Inventor
クロックス，ピーター，エー．
リヴェラ，ミグエル
Original Assignee
ヤウポン セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤウポン セラピューティクス，インコーポレーテッド filed Critical ヤウポン セラピューティクス，インコーポレーテッド
Publication of JP2006510618A publication Critical patent/JP2006510618A/ja
Publication of JP2006510618A5 publication Critical patent/JP2006510618A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/90—Benzo [c] furans; Hydrogenated benzo [c] furans with an oxygen atom in position 1 and a nitrogen atom in position 3, or vice versa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/40—Vinylene carbonate; Substituted vinylene carbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
JP2004553852A 2002-11-18 2003-11-18 ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用 Withdrawn JP2006510618A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42679302P 2002-11-18 2002-11-18
PCT/US2003/036789 WO2004045601A1 (en) 2002-11-18 2003-11-18 Analgesic uses of norketamine and ketamine/norketamine prodrugs

Publications (2)

Publication Number Publication Date
JP2006510618A true JP2006510618A (ja) 2006-03-30
JP2006510618A5 JP2006510618A5 (enExample) 2007-01-25

Family

ID=32326427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004553852A Withdrawn JP2006510618A (ja) 2002-11-18 2003-11-18 ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用

Country Status (9)

Country Link
US (1) US20040248964A1 (enExample)
EP (2) EP1567145B1 (enExample)
JP (1) JP2006510618A (enExample)
AT (1) ATE432697T1 (enExample)
AU (1) AU2003291037A1 (enExample)
CA (1) CA2506615A1 (enExample)
DE (1) DE60327883D1 (enExample)
NZ (1) NZ540282A (enExample)
WO (1) WO2004045601A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015535847A (ja) * 2012-10-08 2015-12-17 オークランド ユニサービシーズ リミティド ケタミン誘導体
KR20170083575A (ko) * 2014-11-04 2017-07-18 아모르사 테라퓨틱스 인코포레이티드 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
JP2018517758A (ja) * 2015-06-19 2018-07-05 インプリミス・ファーマシューティカルズ・インコーポレイテッドＩｍｐｒｉｍｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 麻酔用途のための医薬組成物
JP2019501877A (ja) * 2015-11-19 2019-01-24 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． 医薬化合物のアミンプロドラッグ
KR20190040340A (ko) * 2016-08-31 2019-04-17 다트 뉴로사이언스, 엘엘씨 장애의 치료를 위한 하이드록시노르케타민 유도체
JPWO2018079693A1 (ja) * 2016-10-27 2019-10-31 国立大学法人千葉大学 （ｓ）−ノルケタミンおよびその塩の医薬品としての応用
JP2021510166A (ja) * 2018-01-10 2021-04-15 エックスダブリューファルマ リミテッド ケタミンのプロドラッグ、組成物及びそれらの使用
US11690811B2 (en) 2021-08-13 2023-07-04 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
WO2009131794A1 (en) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
CN102223791A (zh) 2008-09-27 2011-10-19 塔阿克斯有限公司 用于神经病变治疗的局部用制剂
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
EP2454226B1 (en) * 2009-07-16 2017-03-22 Solvay Fluor GmbH Process for the preparation of fluoroalkyl (fluoro)alkyl carbonates
JP6296985B2 (ja) * 2011-10-14 2018-03-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
US20120323214A1 (en) * 2012-05-16 2012-12-20 Totada R Shantha Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
WO2014020155A1 (en) * 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
EP2983787B1 (en) 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
WO2015101693A1 (es) * 2013-12-31 2015-07-09 Servicio Andaluz De Salud Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas
US9610259B2 (en) 2014-01-14 2017-04-04 Children's Hospital Medical Center Compositions and methods for treating an autism spectrum disorder
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
WO2016106329A1 (en) 2014-12-23 2016-06-30 Acelrx Pharmaceuticals, Inc. Systems, devices and methods for dispensing oral transmucosal dosage forms
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
WO2016186968A1 (en) * 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US11111210B2 (en) 2015-11-18 2021-09-07 Spirify Pharma Inc. Phenyl cyclohexanone derivatives and methods of making and using them
US11827606B2 (en) 2015-11-18 2023-11-28 Spirify Pharma Inc. Phenyl cyclohexanone derivatives and methods of making and using them
US11006661B2 (en) * 2016-08-15 2021-05-18 Mamood Valadi Cigarette-like device for administration of substances
US9963435B2 (en) 2016-08-31 2018-05-08 Dart Neuroscience, Llc Compounds for therapeutic use
WO2019033330A1 (en) 2017-08-17 2019-02-21 Xw Laboratories, Inc. PREPARATION AND USES OF DERIVATIVES TRACERS OF OXYGEN REACTIVE SPECIES
EP3988561B1 (en) 2017-09-04 2023-06-07 XWPharma Ltd. Preparation and use of reactive oxygen species scavenger
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
TW201919595A (zh) * 2017-09-27 2019-06-01 國立大學法人千葉大學 作為神經變性疾病或認知機能障礙之預防或治療劑之r-氯胺酮及其衍生物
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
WO2020237747A1 (zh) * 2019-05-24 2020-12-03 北京大学深圳研究生院 一种长效化合物在制备药物中的应用
US11753378B2 (en) * 2021-04-19 2023-09-12 Zevra Therapeutics, Inc. Ketamine compounds and processes for making and using them
EP4289815A1 (en) 2022-06-10 2023-12-13 Pcas Crystalline forms of norketamine
WO2024044355A2 (en) * 2022-08-25 2024-02-29 1/1The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment of alzheimer's disease and other neurogenerative disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407A (en) 1847-12-28 Fence
US713A (en) 1838-04-25 Improvement in many-chambered-cylinder fire-arms
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4879119A (en) 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
US4671953A (en) 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
ATE107176T1 (de) 1989-12-04 1994-07-15 Searle & Co System zur transdermalen albuterol applikation.
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
SE9203743D0 (sv) 1992-12-11 1992-12-11 Astra Ab Efficient use
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
CA2230690C (en) * 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
CA2270531C (en) * 1996-11-05 2011-08-30 Head Explorer Aps A method for treating tension-type headache
AU756136B2 (en) 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US6406745B1 (en) 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US20050148673A1 (en) * 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015535847A (ja) * 2012-10-08 2015-12-17 オークランド ユニサービシーズ リミティド ケタミン誘導体
KR20170083575A (ko) * 2014-11-04 2017-07-18 아모르사 테라퓨틱스 인코포레이티드 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
KR102604397B1 (ko) * 2014-11-04 2023-11-21 아카디아 파마슈티칼스 인코포레이티드 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
JP2018517758A (ja) * 2015-06-19 2018-07-05 インプリミス・ファーマシューティカルズ・インコーポレイテッドＩｍｐｒｉｍｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 麻酔用途のための医薬組成物
JP2019501877A (ja) * 2015-11-19 2019-01-24 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． 医薬化合物のアミンプロドラッグ
JP7110094B2 (ja) 2015-11-19 2022-08-01 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 医薬化合物のアミンプロドラッグ
KR20190040340A (ko) * 2016-08-31 2019-04-17 다트 뉴로사이언스, 엘엘씨 장애의 치료를 위한 하이드록시노르케타민 유도체
JP2019524899A (ja) * 2016-08-31 2019-09-05 ダート・ニューロサイエンス・エルエルシー 障害の治療のためのヒドロキシノルケタミン誘導体
KR102471059B1 (ko) 2016-08-31 2022-11-25 다트 뉴로사이언스, 엘엘씨 장애의 치료를 위한 하이드록시노르케타민 유도체
JP7033139B2 (ja) 2016-08-31 2022-03-09 ダート・ニューロサイエンス・エルエルシー 障害の治療のためのヒドロキシノルケタミン誘導体
JP2022081648A (ja) * 2016-10-27 2022-05-31 国立大学法人千葉大学 （ｓ）－ノルケタミンおよびその塩の医薬品としての応用
JPWO2018079693A1 (ja) * 2016-10-27 2019-10-31 国立大学法人千葉大学 （ｓ）−ノルケタミンおよびその塩の医薬品としての応用
JP2022516575A (ja) * 2018-01-10 2022-02-28 エックスダブリューファルマ リミテッド ケタミン誘導体およびその組成物
US11440874B2 (en) 2018-01-10 2022-09-13 XWPharma Ltd. Ketamine derivatives and compositions thereof
JP7167168B2 (ja) 2018-01-10 2022-11-08 エックスダブリューファルマ リミテッド ケタミンのプロドラッグ、組成物及びそれらの使用
JP2021510166A (ja) * 2018-01-10 2021-04-15 エックスダブリューファルマ リミテッド ケタミンのプロドラッグ、組成物及びそれらの使用
JP2023017818A (ja) * 2018-01-10 2023-02-07 エックスダブリューファルマ リミテッド ケタミンのプロドラッグ、組成物及びそれらの使用
US12209060B2 (en) 2018-01-10 2025-01-28 XWPharma Ltd. Ketamine derivatives and compositions thereof
US11690811B2 (en) 2021-08-13 2023-07-04 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives
US12396966B2 (en) 2021-08-13 2025-08-26 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Also Published As

Publication number Publication date
CA2506615A1 (en) 2004-06-03
US20040248964A1 (en) 2004-12-09
NZ540282A (en) 2008-06-30
DE60327883D1 (de) 2009-07-16
HK1079461A1 (en) 2006-04-07
ATE432697T1 (de) 2009-06-15
EP1567145B1 (en) 2009-06-03
WO2004045601A1 (en) 2004-06-03
EP1567145A1 (en) 2005-08-31
AU2003291037A1 (en) 2004-06-15
EP2027854A1 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
EP1567145B1 (en) Analgesic uses of (s)-norketamine
US5543434A (en) Nasal administration of ketamine to manage pain
US6248789B1 (en) Administration of ketamine to manage pain and to reduce drug dependency
RU2438660C2 (ru) Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
CA2230690C (en) Administration of ketamine to manage pain and to reduce drug dependency
MXPA96003633A (en) Use of ketamine and device for the nasal and eye administration of ketamine for the management of pain and for detoxification
US20090061024A1 (en) Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect
US5989582A (en) Administration of ketamine for detoxification and to treat substance addiction, and compositions therefor
CA2688542C (en) Methods and compositions for administration of oxybutynin
AU733284B2 (en) Nasal and ocular administration of ketamine to manage pain and for detoxification
JP2005531612A (ja) ネフォパムの製剤および痛みの治療におけるその使用
CA3159436A1 (en) Use of a kv7 potassium channel opener for treating pain
US20080132531A1 (en) Synergistic combinations of norketamine and opioid analgesics
US20080207667A1 (en) Use of nalbuphine and related compounds to treat symptoms of respiratory problems
WO2005060957A1 (en) Formulation of nefopam and its use in the treatment of pain
Ko Acute pain management
HK1079461B (en) Analgesic uses of (s)-norketamine
JP2009515907A (ja) ノルケタミン及びオピオイド鎮痛薬の相乗的な組み合わせ
US20070244102A1 (en) Combination of Dermaciclane and Opoids as Analgesics
Malviya et al. Deciphering the Pain-Relieving Double-Edged Sword
CA2596947A1 (en) Nasal and ocular administration of ketamine to manage pain and for detoxification
HK1150196A (en) Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061116

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091204